Liquid biopsy at home in 2025: MCED screening vs MRD monitoring

Medical review: Reviewed by Gary A. Webb MD MS FAAFP, Medical Director at HealthE1 Mobile Medical Services on October 14, 2025. Fact-checked against government and academic sources; see in-text citations. This page follows our Medical Review & Sourcing Policy and undergoes updates at least every six months. Last updated January 17, 2026.

Takeaways

• MCED and MRD liquid biopsies serve different goals—early detection vs. post-treatment monitoring.
• At-home blood draws are reliable if done correctly, but logistics like timing and labeling matter.
• Regulatory clearance and clinical utility for these tests are expanding, but remain partially investigational.

What “at-home liquid biopsy” actually means in 2025

At-home liquid biopsy in 2025 refers to a coordinated process that enables patients to undergo advanced blood-based cancer testing without visiting a clinical site. It requires a physician order for both MCED (multi-cancer early detection) and MRD (molecular residual disease) assays. Once approved, eligible patients receive a collection kit designed for mobile phlebotomy use or clinic-based draw.

Mobile phlebotomy networks now support scheduled home visits across most U.S. metro areas, typically coordinated through telehealth consults or primary care referrals. Patients select a date, and a trained professional collects the sample using proprietary cfDNA preservation tubes.

Stabilization tubes allow room-temperature transport for up to 7 days without DNA degradation. Phlebotomists must follow strict chain-of-custody protocols including labeled tubes, timely shipment, and verified handoffs. Any deviation compromises result accuracy and may trigger a recollection. HealthE1 Mobile Medical Services has standardized these mobile workflows to maintain specimen integrity and minimize patient inconvenience.

Two very different goals: MCED screening vs MRD monitoring

MCED screening aims to detect cancer signals in asymptomatic adults who have no prior diagnosis. It does not focus on a specific tumor type but scans for shared cancer-derived signals across tissue types. Patients often undergo this test as a supplement to standard screening methods like mammography or colonoscopy.

MRD monitoring, on the other hand, targets a different group: cancer survivors. These tests search for trace amounts of tumor-derived DNA following curative-intent therapy. Oncologists use them to assess recurrence risk, guide surveillance intervals, or evaluate adjuvant therapy timing.

MCED assays often rely on epigenetic methylation signatures or multi-analyte panels. In contrast, MRD tests typically use tumor-informed ctDNA assays that detect mutations unique to the individual’s cancer. Each test type serves a distinct clinical purpose, and misunderstanding this distinction leads to inappropriate use or misinterpretation of results.

What’s available today in the U.S.

In the MCED space, two notable CLIA laboratory-developed tests are accessible in 2025: Galleri and Cancerguard. Both are prescription-only and ordered through a licensed provider. These tests report the presence or absence of a cancer signal and predict a tissue of origin to guide follow-up.

MRD tests include Signatera, Reveal, and other assays designed for colorectal, lung, breast, and urothelial cancers. Some are tumor-informed, requiring tissue profiling, while others are tumor-naive. These are commonly used during remission monitoring phases.

Patients gain access either through their oncologist or through emerging partnerships with DPC and concierge care groups. Reimbursement varies, though Medicare increasingly covers MRD assays for high-risk CRC patients. HealthE1 Mobile Medical Services coordinates with oncologists and labs to support in-home draws for these tests when appropriate.

Regulatory and guideline landscape in 2025

As of October 2025, no MCED test has full FDA approval. Both Galleri and Cancerguard remain CLIA-certified LDTs. However, registrational trials are underway, including a pivotal study for Galleri designed to meet FDA diagnostic standards.

The NCCN recognizes the prognostic power of ctDNA-based MRD tests in several cancers but stops short of recommending them for surveillance-based treatment decisions outside trials. ASCO mirrors this cautious stance, highlighting the potential but also the risks of premature clinical application.

Several landmark studies are expected to report outcomes in 2026, including NHS-Galleri and NRG-GI005 COBRA. Their results could dramatically shift regulatory attitudes and payer policies in the next 12 to 24 months.

Analytical performance: sensitivity, specificity, PPV, and cancer-signal origin

Galleri’s PATHFINDER data show a specificity of ~99.5%, limiting false positives. In the second PATHFINDER study, the reported positive predictive value improved to 58% due to refined signal-calling algorithms and better pre-test population matching. Cancerguard reports 97.4% specificity but awaits real-world validation.

The Cancers journal review outlines how ctDNA MRD detection could influence adjuvant chemotherapy by identifying patients with higher risk of recurrence.

The NHS-Galleri trial targets a 25% stage III/IV reduction over 3 years. Its final outcomes will influence adoption decisions across national systems. Unlike MCEDs, MRD tests reach much higher sensitivity because they hunt for known mutations in a low-background setting.

MRD detection often precedes radiographic recurrence by several months, enabling earlier intervention. However, sensitivity can drop when ctDNA shedding is low, such as in low-burden or mucinous tumors.

Clinical utility evidence: what changes for patients?

MCED testing may detect cancers not typically covered by standard screenings, such as pancreatic or ovarian cancers. However, its clinical utility depends on effective downstream diagnostics and timely imaging. Studies show that patients with true-positive MCED results benefit from faster treatment initiation.

In urothelial carcinoma studies, ctDNA MRD positivity has correlated strongly with early relapse, supporting its prognostic value beyond colorectal cancer.

For MRD, its primary value lies in personalized risk stratification. A positive result post-surgery indicates residual disease, prompting closer surveillance or additional therapy. Trials have demonstrated that MRD-guided management can delay recurrence in some cancers.

Still, routine use remains investigational in many contexts. Clinical teams must evaluate each patient’s disease, treatment history, and recurrence risk before integrating MRD insights into care plans.

False positives, false negatives, and confirmatory workflows

False positives in MCED tests often arise from clonal hematopoiesis of indeterminate potential (CHIP). These are non-cancerous mutations that mimic tumor signals in blood. Labs increasingly use bioinformatics filters to reduce CHIP interference, but some signals still slip through.

A WUSTL genomic review describes how CHIP noise complicates ctDNA interpretation and outlines methods to increase analytical confidence.

Given cancer prevalence and PPV limitations, a positive MCED requires confirmatory imaging, typically whole-body PET-CT or MRI. Negative scans may prompt short-term re-testing or referral to oncology for close monitoring.

MRD tests can also yield false negatives when tumor DNA is not present in sufficient quantity. This can occur due to low disease burden or limited ctDNA shedding. Therefore, a negative MRD result does not rule out recurrence and should not replace traditional imaging.

11K+ Satisfied Clients – 8K+ Blood Drawn – 25+ Years in Business – 17K+ IV Solutions Given

At-home draw logistics that affect accuracy

Accurate at-home draws depend on phlebotomist experience. Critical factors include filling the correct tube volume, inverting tubes to mix stabilizers, and labeling without error. Poor technique leads to invalid or delayed results.

Stabilization tubes protect cfDNA for up to 7 days at room temperature. Still, delays beyond 72 hours can compromise integrity, especially during holidays or extreme weather. Labs flag aged specimens and may reject them outright.

Certain patients, including those with mobility issues or difficult veins, may benefit more from clinic draws. HealthE1 Mobile Medical Services pre-screens candidates to determine the safest and most efficient draw location.

Comparison table: MCED screening vs MRD monitoring

Feature	MCED Screening	MRD Monitoring
Intended Use	Cancer detection in asymptomatic adults	Recurrence detection in survivors
Eligible Population	Adults 50+, no known cancer	Post-treatment cancer patients
Assay Type	Methylation-based, multi-omic	Tumor-informed ctDNA
Reported Specificity	97.4–99.5%	>99%
Typical PPV Context	30–58% depending on study	80–90% in known cancer
Follow-up Pathway	Imaging, tissue confirmation	Oncology-directed intervention
Guideline Status	Investigational	Prognostic, limited clinical use
At-home Draw Availability	Yes	Yes
Turnaround Time	10–14 days	7–10 days

Which patients should consider MCED vs MRD in 2025

MCED testing suits average-risk adults aged 50 and older who are up to date on routine screenings. It offers potential value in detecting cancers like pancreatic, which lack standard screening protocols. Shared decision-making helps patients weigh costs and benefits.

MRD suits individuals recently treated for cancer with curative intent. It is especially relevant for colorectal, breast, and lung cancer survivors within two years of treatment. Oncologists use it to fine-tune post-treatment surveillance schedules.

High-risk groups, including patients with hereditary syndromes or multiple cancers, may benefit from both types. Providers should align testing strategies with personal and family history, imaging access, and anxiety levels about recurrence.

Health-system and primary-care workflow implications

A positive MCED test prompts a diagnostic cascade requiring specialty coordination. Systems need predefined imaging order sets and rapid oncology referrals to manage patient flow. Without this, testing creates uncertainty rather than clarity.

Informed consent forms must explain residual risk and false-positive rates. Patients must also understand that the absence of a signal does not guarantee absence of cancer.

Financial counseling plays a role as MCED tests cost over $800 out-of-pocket. Clinics benefit from pre-verifying insurance for MRD and preparing alternative payment options. HealthE1 Mobile Medical Services integrates patient education and consent verification into its mobile protocol.

Data privacy, sample retention, and reanalysis policies

Labs retain plasma samples for 6 to 12 months, with some offering reflex reanalysis when new targets emerge. Data derived from these samples may feed machine-learning models used for test optimization.

Patients can request data deletion, but that may limit reanalysis or genetic insight availability. HIPAA-compliant systems protect identifiable information, but secondary use for algorithm training often lacks opt-in consent.

HealthE1 Mobile Medical Services provides clear documentation outlining lab policies and offers support for patients concerned about data use or long-term storage.

3 Practical Tips

• Schedule your at-home blood draw early in the week to ensure same-week delivery to the lab. Avoid scheduling before holidays to reduce transit delays or specimen aging.
• Ask your doctor about the next steps if your test result is positive. This includes identifying which imaging tests will follow and where they will occur.
• Keep routine screenings like mammograms, FIT tests, or LDCTs current. These remain the frontline tools, while MCED and MRD serve as supplemental resources.

What to watch next in 2025–2026

Trial outcomes expected in 2026 could change how MCED and MRD tests are used. These include the final NHS-Galleri data and the COBRA trial on MRD-guided colorectal cancer management.

New non-blood liquid biopsies, such as exhaled breath and urine multi-omics, are under development. They aim to expand the ease and reach of at-home cancer testing.

Medicare may expand MRD coverage in 2026, particularly for high-risk lung and breast cancer survivors. Commercial payers often follow CMS precedent, making this a pivotal period.

FAQ

Can an MCED test replace routine mammograms, colon screening, or LDCT?
No. MCED tests do not replace existing guideline-based screenings. Mammograms, colonoscopies, and low-dose CT remain essential. MCED provides a broad scan for other hard-to-detect cancers, but standard tools still catch most cases.

How often is MRD testing done after curative-intent therapy, and for how long?
MRD is typically performed every three to six months during the first two years post-treatment. This interval may vary depending on cancer type and recurrence risk. Some clinicians extend monitoring to five years for high-risk cases.

What happens after a positive MCED result if imaging is negative?
Doctors may recommend short-term surveillance with follow-up imaging. Some cases lead to specialist referral for further evaluation. A positive signal without clinical evidence of disease can cause anxiety, so supportive counseling often follows.

Are at-home draws as reliable as clinic draws for ctDNA tests?
Yes, when conducted by trained phlebotomists following validated protocols. Home draws require proper tube filling, inversion, and packaging. Errors can occur in either setting, but experienced mobile teams like HealthE1 mitigate those risks effectively.